Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Corcept Therapeutics Incorporated”

120 pharma patents match "Corcept Therapeutics Incorporated" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 120
Index total 30,257
Page 4 / 5

Quick answer

This filtered view shows 120 pharmaceutical patents matching "Corcept Therapeutics Incorporated" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

120 results for “Corcept Therapeutics Incorporated” · 30,257 patents in full index Clear search

  1. US 10413540

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted

  2. US 10323034

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Jun 18, 2019 · Expires Jun 13, 2039

    granted

  3. US 10314850

    Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Corcept Therapeutics Incorporated · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted

  4. US 10238659

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  5. US 10231983

    Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients

    Corcept Therapeutics Incorporated · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  6. US 10213414

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Feb 26, 2019 · Expires Feb 21, 2039

    granted

  7. US 10195214

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Corcept Therapeutics Incorporated · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted

  8. US 10166243

    Optimizing mifepristone levels for cushing'S patients

    Corcept Therapeutics Incorporated · Granted Jan 1, 2019 · Expires Dec 27, 2038

    granted

  9. US 10166242

    Optimizing mifepristone levels for Cushing's patients

    Corcept Therapeutics Incorporated · Granted Jan 1, 2019 · Expires Dec 27, 2038

    granted

  10. US 10151763

    Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome

    Corcept Therapeutics Incorporated · Granted Dec 11, 2018 · Expires Dec 6, 2038

    granted

  11. US 10117852

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Nov 6, 2018 · Expires Nov 1, 2038

    granted

  12. US 10047082

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted

  13. US 10006924

    Method for differentially diagnosing ACTH-dependent cushing's syndrome

    Corcept Therapeutics Incorporated · Granted Jun 26, 2018 · Expires Jun 21, 2038

    granted

  14. US 9977875

    Systems and methods of managing treatment of a chronic condition by symptom tracking

    Corcept Therapeutics Incorporated · Granted May 22, 2018 · Expires May 17, 2038

    granted

  15. US 9956216

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted May 1, 2018 · Expires Apr 26, 2038

    granted

  16. US 9943505

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Apr 17, 2018 · Expires Apr 12, 2038

    granted

  17. US 9943526

    Optimizing mifepristone levels for cushing's patients

    Corcept Therapeutics Incorporated · Granted Apr 17, 2018 · Expires Apr 12, 2038

    granted

  18. US 9829495

    Method for differentially diagnosing ACTH-dependent Cushing's syndrome

    Corcept Therapeutics Incorporated · Granted Nov 28, 2017 · Expires Nov 23, 2037

    granted

  19. US 9707223

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Jul 18, 2017 · Expires Jul 13, 2037

    granted

  20. US 9321736

    Pyrimidine cyclohexyl glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Apr 26, 2016 · Expires Apr 21, 2036

    granted

  21. US 9273047

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Mar 1, 2016 · Expires Feb 25, 2036

    granted

  22. US 8921348

    Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  23. US 8906917

    Pyrimidine cyclohexyl glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Dec 9, 2014 · Expires Dec 4, 2034

    granted

  24. US 8889867

    Solid forms and process for preparing

    Corcept Therapeutics Incorporated · Granted Nov 18, 2014 · Expires Nov 13, 2034

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.